Lupin Ltd

Past performance
Performance overview
Lupin Ltd
About Lupin Ltd Lupin Limited is a global pharmaceutical company known for its innovation-led approach in developing and marketing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It holds a robust presence in therapy areas including Cardiovascular, Diabetology, Asthma, CNS, GI, Anti-Infective, and NSAIDs. Notably, Lupin is a global leader in Anti-TB and Cephalosporins segments. Established in 1983, Lupin has expanded its footprint through strategic acquisitions, such as Kyowa Pharmaceutical in Japan, and Hormosan Pharma in Germany, enhancing its global market reach. The company has a significant manufacturing and research presence, with facilities in India and international markets like the US, Japan, and Australia. Recent strategic moves include acquiring Southern Cross Pharma in Australia, expanding into the specialty injectables space with Medisol in France, and launching new products like the orphan drug 'Namuscla'. Lupin continues to enhance its specialty business portfolio with acquisitions and strategic alliances, emphasizing its commitment to providing accessible healthcare solutions globally. As of 2023, Lupin operates with 28 subsidiaries and a joint venture.
Website lupin.com
Founded 1983
Headquarters Mumbai